Accelerate Diagnostics

Accelerate Diagnostics Goodwill

Delisted

The Goodwill of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 114,000.00 USD. In the previous year, Goodwill was 134,000.00 USD — a change of -14.93% (lower).

Goodwill

114,000.00USD

YoY

-14.93%

Last updated:

Goodwill of Accelerate Diagnostics is 2018 114,000.00 USD. Goodwill of Accelerate Diagnostics was 2017 134,000.00 USD. It decreases by -14.93% lower compared to the previous year.

The Accelerate Diagnostics Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2014
167,000.00 USD
Jan 1, 2015
157,000.00 USD
Jan 1, 2016
146,000.00 USD
Jan 1, 2017
134,000.00 USD
Jan 1, 2018
114,000.00 USD
The Accelerate Diagnostics Goodwill history
YEARGoodwillYoY
114,000.00USD-14.93%
134,000.00USD-8.22%
146,000.00USD-7.01%
157,000.00USD-5.99%
167,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Goodwill of Accelerate Diagnostics is 114,000.00 USD in 2018.

Goodwill of Accelerate Diagnostics changed from 134,000.00 USD to 114,000.00 USD, representing a -14.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics